We provide you with 20 years of free, institutional-grade data for RAPT stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of RAPT. Explore the full financial landscape of RAPT stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Braunstein Scott | Grant, award...etc | 4,956 | 2026-02-02 | ||
| Giordano Michael F | Grant, award...etc | 4,956 | 2026-02-02 | ||
| GRAY MARY ANN | Grant, award...etc | 4,956 | 2026-02-02 | ||
| Lyons-Williams Lori | Grant, award...etc | 4,956 | 2026-02-02 | ||
| Kozick Linda | Grant, award...etc | 4,956 | 2026-02-02 | ||
| Dombkowski Ashley L. | Grant, award...etc | 4,956 | 2026-02-02 | ||
| Brockstedt Dirk G. | Sale | -898 | $22.78 | $20,456 | 2024-01-08 |
| Brockstedt Dirk G. | Derivatives Exercise | 8,000 | 2024-01-02 | ||
| HO WILLIAM | Sale | -2,500 | $21.68 | $54,200 | 2023-12-22 |
| HO WILLIAM | Sale | -1,500 | $13.72 | $20,580 | 2023-11-29 |
| HO WILLIAM | Sale | -2,500 | $15.77 | $39,425 | 2023-10-04 |
| HO WILLIAM | Sale | -2,500 | $18.92 | $47,300 | 2023-08-22 |
| HO WILLIAM | Derivatives Exercise | 460 | 2023-08-03 | ||
| HO WILLIAM | Derivatives Exercise | 920 | 2023-06-27 | ||
| HO WILLIAM | Sale | -5,000 | $18.88 | $94,400 | 2023-04-20 |
| HO WILLIAM | Derivatives Exercise | 460 | 2023-04-14 | ||
| Robbins Wendye | Open Market Purchase | 2,500 | $20.05 | 2023-03-15 | |
| Robbins Wendye | Open Market Purchase | 2,500 | $18.75 | 2023-03-15 | |
| HO WILLIAM | Sale | -5,000 | $29.62 | $148,100 | 2023-03-13 |
| HO WILLIAM | Derivatives Exercise | 460 | 2023-03-06 |
The information provided in this report about RAPT stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
RAPT Therapeutics, Inc(NASDAQ:RAPT) 
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small m...
Website: http://www.flxbio.com
Founded: 2015
Full Time Employees: 71
CEO: Brian Russell Wong
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends